Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not discloseda
abrdn
Activity from announced rounds
Activity in this selectionUnited States · Oct 4, 2026 · Jul 7, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $156M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosed